Bionano Genomics CMO Alka Chaubey resigns
Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned. The resignation was submitted on June 2, 2026 and will be effective July 5, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BNGO.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation notice date: June 2, 2026
Resignation effective date: July 5, 2026
Par value per share: $0.0001 per share
+1 more
4 metrics
Resignation notice date
June 2, 2026
Date CMO resignation was submitted
Resignation effective date
July 5, 2026
Date CMO role ends
Par value per share
$0.0001 per share
Common stock par value
Company phone number
(858) 888-7600
Principal executive office phone
Key Terms
Emerging growth company, Chief Medical Officer, Interim Chief Executive Officer, Exchange Act
4 terms
Emerging growth company regulatory
"Emerging growth company Departure of Chief Medical Officer"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Chief Medical Officer financial
"June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Interim Chief Executive Officer financial
"Albert A. Luderer, Ph.D. Interim Chief Executive Officer"
An interim chief executive officer is a temporary leader appointed to run a company while the board searches for a permanent CEO or manages an unexpected departure. Investors pay attention because this person shapes near-term strategy, stability and market confidence—like a substitute driver steering the car until the regular driver returns—and their actions and credibility can influence share price, hiring and major deals.
Exchange Act regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did Bionano Genomics (BNGO) disclose in this 8-K?
Bionano Genomics disclosed the resignation of its Chief Medical Officer. The filing states that Alka Chaubey, Ph.D. resigned from the Chief Medical Officer role, with an effective date of July 5, 2026, following notice provided on June 2, 2026.
When is Bionano Genomics Chief Medical Officer Alka Chaubey, Ph.D. leaving?
Alka Chaubey, Ph.D. will leave Bionano Genomics on July 5, 2026. According to the filing, she resigned as Chief Medical Officer on June 2, 2026, with her resignation scheduled to become effective in early July 2026.
What role does Albert A. Luderer, Ph.D. hold at Bionano Genomics (BNGO)?
Albert A. Luderer, Ph.D. serves as Interim Chief Executive Officer. He signed the report on behalf of Bionano Genomics, Inc., indicating his position as interim CEO at the time of the leadership change involving the Chief Medical Officer.
On which exchange is Bionano Genomics common stock listed and under what symbol?
Bionano Genomics common stock trades on the Nasdaq Capital Market as BNGO. The filing confirms that its common stock, with a par value of $0.0001 per share, is registered under the trading symbol BNGO on the Nasdaq Capital Market.
What type of company is Bionano Genomics under SEC definitions?
Bionano Genomics is identified as an emerging growth company. The filing references status under Rule 405 of Regulation C and Rule 12b-2 of the Exchange Act, indicating the company qualifies as an emerging growth company for SEC reporting purposes.
What is Bionano Genomics’ principal executive office address?
Bionano Genomics’ principal executive offices are in San Diego, California. The filing lists the address as 9540 Towne Centre Drive, Suite 100, San Diego, California 92121, which is the company’s main business location for executive operations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates